BGBIO Relative Valuation - Bergenbio ASA - Alpha Spread
B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 9.07 NOK 1.06% Market Closed
Market Cap: 368.3m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Relative Value

The Relative Value of one BGBIO stock under the Base Case scenario is 0.2 NOK. Compared to the current market price of 9.07 NOK, Bergenbio ASA is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BGBIO Relative Value
Base Case
0.2 NOK
Overvaluation 98%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
5
Median 3Y
33 609.5
Median 5Y
55 034.4
Industry
7.7
Forward
5 363.4
vs History
vs Industry
Median 3Y
-73.7
Median 5Y
-206.3
Industry
23.9
Forward
-1.7
vs History
vs Industry
Median 3Y
-74.5
Median 5Y
-218.9
Industry
22.2
vs History
vs Industry
Median 3Y
-74.4
Median 5Y
-218.5
Industry
24
vs History
88
vs Industry
16
Median 3Y
148
Median 5Y
158.9
Industry
2.5
vs History
92
vs Industry
4
Median 3Y
33 318.7
Median 5Y
54 657.8
Industry
7.4
Forward
3 654.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-72.5
Median 5Y
-202.8
Industry
5.1
Forward
-1.3
vs History
vs Industry
Median 3Y
-72.2
Median 5Y
-202
Industry
4.7
Forward
-1.3
vs History
vs Industry
Median 3Y
-73.8
Median 5Y
-217.5
Industry
6.6
vs History
vs Industry
Median 3Y
-73.8
Median 5Y
-217.5
Industry
4.7
vs History
vs Industry
3
Median 3Y
-1 345.6
Median 5Y
-3 757.7
Industry
4.7

Multiples Across Competitors

BGBIO Competitors Multiples
Bergenbio ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Bergenbio ASA
OSE:BGBIO
368.3m NOK 706.9 -2.4 -1.6 -1.6
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 28
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/E: 57.6
Negative Multiple: -2.4
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/EBITDA: 47.8
Negative Multiple: -1.6
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/EBIT: 69.5
Negative Multiple: -1.6
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
28
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top